Product News

Lipercosyl® is the first statin and ACEi combination available in Ireland.

Servier Laboratories (Ireland) Ltd are delighted to announce that Lipercosyl®, the combination of atorvastatin and perindopril, will be available for prescription from February 2021 and is listed as a PCRS reimbursable product.

This image has an empty alt attribute; its file name is lipercosyl-single-783x1024.jpg

Lipercosyl® is the first statin and ACEi combination available in Ireland12. It controls both high cholesterol and hypertension in tandem1. This combination will help patients achieve their lower LDL-C and blood pressure targets4,5.

Atorvastatin has been shown to reduce concentrations of LDL-C by up to 49% 2and perindopril reduces BP by 18.5/9.7mmHg3 helping patients reach lower targets4,5. Perindopril’s antihypertensive activity is sustained for at least 24 hours and atorvastatin is a long-acting statin, ensuring true 24hr control from a single daily dose1.

A major benefit of Lipercosyl® is by combining a lipid-lowering therapy with perindopril there is a 22% relative risk reduction in cardiovascular mortality, non-fatal acute MI and cardiac arrest with successful resuscitation as seen in a EUROPA subgroup analysis1. ESC Guidelines  recommend adding a statin to antihypertensive treatment for patients with high cardiovascular risk.4

Prescribing the 2 agents in a single pill combination offers patients better efficacy, tolerability and adherence.1,6,7

Lipercosyl® is a combination product which is indicated as substitution therapy as part of cardiovascular risk management, in adult patients adequately controlled with atorvastatin and perindopril given concurrently at the same dose level but as separate products1.

Lipercosyl is available in 6 strengths1,*:

This image has an empty alt attribute; its file name is Lipercosyl-1024x1024.jpg

Should you require any further information, please contact Servier on 01 6638110, or refer to the full Summary of Product Characteristics on

Background information:

Cardiovascular disease (CVD) remains the leading cause of death in Ireland10, and high serum cholesterol is an important modifiable risk factor for the development of CVD11. A new approach to the prevention of cardiovascular disease shows that the earlier and the longer BP and LDL-C are controlled, the greater the reduction in cardiovascular events. Recent data published from the TILDA study (The Irish Longitudinal Study on Ageing) reports that the most common co-morbidities are hypertension and high cholesterol. Over 50% of the people who have hypertension also have high cholesterol9.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.615 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servicer’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

References 1. Lipercosyl SmPC, Dec 2019. 2. Law MR. et al. BMJ 2003;326(7404):1423 3. Tsoukas G et al, Am J Cardiovasc Drugs. 2011:11(1):45-55. 4. Williams B et al. Eur Heart J. 2018:39(33):3021-3104. 5. Mach et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias, European Heart Journal (2019) 00, 1-78. * Patients with: documented CVD, Diabetes Mellitus with organ damage, Severe CKD (chronic kidney disease), a calculated 10 year risk of fatal CVD ≥ 10%, Familial Hypercholesterolaemia with CVD/risk factor. ** Patients with: Markedly elevated single risk factors (in particular cholesterol > 8mmol/L or BP ≥ 180/110 mmHg), Familial Hypercholesterolaemia, Diabetes Mellitus, Moderate CKD (chronic kidney disease), a calculated 10 year risk of fatal CVD ≥ 5% and <10%. 6. Poulter NR et al, Medication adherence in Hypertension, J Hypertens 2019:37 doi:10.1099/HJH0000000000002294 7. Iellamo F et al, Cardiac Failure Review 2017;3(1):40-45. 8. Gidding S. JACC. 2019;23;342-345 9. Hernandez, B., et al. 1October 2019, Scientific Reports, Nature reports. n=6,101 Irish Adults. TILDA 2019 10. CSO Statistical publication of mortality in 2018 – 31/05/2019 11. Barnes, A., Emerging Modifiable Risk Factors for Cardiovascular Disease ,Tex Heart Inst J. 2013; 40(3): 293–295. 12. IMS, C11A Monthly Unit Sales, July 2020 *Prices quoted are PCRS prices.

Leave a Reply

Your email address will not be published. Required fields are marked *

Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?